Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

nd consumer health products. The Novartis Group is the only company with leading positions in each of these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

About GINECOGroupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO) is a French cooperative trial group of clinicians dedicated to metastatic breast and gynecological cancers. GINECO includes 100 oncology sites (public and private) and 600 investigators. Main GINECO objectives are to promote top-level clinical research and to contribute to define a national policy to fight against cancer, for the sake of patient and society, through a better use of resources. For more information, please visit http://www.arcagy.org.

* XIENCE V® AND XIENCE PRIME™ are registered trademarks of Abbott

** PROMUS™ AND PROMUS™ ELEMENT are registered trademarks of Boston Scientific

References

  1. Bachelot et al. TAMRAD: A GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI). 33rd San Antonio Breast Cancer Symposium. 2010.
  2. O'Shaughnessy J. Extending Survival with Chemotherapy in Metastatic Breast Cancer. The Oncologist. 2005;10(
    '/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- ... a new specialty pharmaceutical company dedicated to ... innovative injectable and sustained release drug therapies ... medical needs, today announced the acquisition of ... Technology®) platform and associated product pipeline. Acquisition ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: ... that VPII Escrow Corp., a newly formed wholly owned ... of approximately $3.2 billion aggregate principal amount of senior ... in 2021 and in 2023, with final tranching determined ... the net proceeds from the offering, together with proceeds ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of ... announced today the publication of the National Osteoporosis ... management of osteoporosis in postmenopausal women and older ... Published in 2009 in Maturitas , the ... update is timely with an additional focus on ...
(Date:6/19/2013)... June 19, 2013 Ultimate Medical Academy ... an 11.5-hour broadcast on WFLA News Channel 8. Since ... more than $84 million for All Children's Hospital in ... themed "30 Years of Miracles," marked the second year ... UMA employees worked the phones during the Telethon, which ...
(Date:6/19/2013)... Next Thursday, June 27, 2013, ... organization, and Muzzy Lane Software , a ... the Games for Health community to their interactive ... toward students in grades 4-7 and designed to ... positive choices. The game is part of a ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on hand ... in a series of six workshops where people with and without ... the mosaic tiles in their permanent location under the direction of ... Maxwell. , This mural project began in March of 2013 ... three years ago with the goal of promoting ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Maui'd ... is dedicated to being an effective and cost effective ... needs. They have partnered up with Tom Barefoot’s Tours ... discounts on most of Hawaii’s activities. , They have ... clients can get the lowest prices on their Hawaii ...
Breaking Medicine News(10 mins):Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2
... Support the Long Term Mental Health Needs ... SAN DIEGO, Oct. 24 As the hundreds of,thousands San ... what,happened and deal with the stress of the situation. These ... those directly and,indirectly affected. In the days, weeks and months ...
... Support The Cause In A Variety Of Ways ..., ... the,team,s First Annual Breast Cancer Awareness Night on Friday, October ... Joe Louis Arena. Doors open,at 6 p.m. for the 7:30 ... Hockey Fights Cancer month when all NHL players wore special ...
... MONTREAL, Oct. 24 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX ... to,announce a new two-phase strategy to have a ... for its lead product candidate, the,Hemaseel(R)HMN fibrin sealant, ... This "First-Patient-In" objective is a major milestone ...
... M. Foley, MD,of Memorial Sloan-Kettering Cancer Center in ... University of Utah School of Medicine, received the ... 2007 at the 9th,Annual Josefina Magno Conference on ... of palliative care, the science of pain and,symptom ...
... reduced toxicity, studies find, , , WEDNESDAY, Oct. 24 (HealthDay ... to the standard two-drug regimen used for head and ... reducing the toxicity, two new studies report. , The ... increased survival in both studies and more than doubled ...
... Norway October 24, 2007 - The use of ... increased incidence of reproductive endocrine disorders in both men ... the effects of withdrawal from two common AEDs, carbamazepine ... and female AED users. , The study finds ...
Cached Medicine News:Health News:San Diego Wildfires Mental Health Fund 2Health News:San Diego Wildfires Mental Health Fund 3Health News:Red Wings Host Breast Cancer Awareness Night 2Health News:Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials 2Health News:Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials 3Health News:Two Physicians Recognized for Work in Pain and Symptom Management 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: